Background: Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies are effective and well-tolerated therapies for migraine prevention. However, up to 30–40% of patients do not respond. While some clinical features have been associated with treatment outcomes, evidence remains limited. Methods: We conducted a retrospective study of patients with episodic or chronic migraine followed at a tertiary head...
Objectives: We conducted a meta-analysis to assess the frequency of incomplete recovery from multiple sclerosis (MS) relapses and a systematic review to evaluate the influence of six factors on incomplete recovery: relapse severity, age, sex, disease duration, disease-modifying treatment use, and the presence of contrast-enhancing lesions at relapse. Methods: We searched Scientific databases to identify suitabl...
N/A.; N/A.